91 related articles for article (PubMed ID: 23589315)
1. Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors.
Deeken JF; Shimkus B; Liem A; Hill D; Gurtler J; Berghorn E; Townes L; Lu H; Trifan O; Zhang S
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1473-83. PubMed ID: 23589315
[TBL] [Abstract][Full Text] [Related]
2. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Barbey JT; Pezzullo JC; Soignet SL
J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
[TBL] [Abstract][Full Text] [Related]
3. Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer.
Borin MT; Chen M; Mocci S; Rubets I; Chittenden J; Aldairy W; Stroh M
Cancer Chemother Pharmacol; 2015 Feb; 75(2):401-10. PubMed ID: 25542267
[TBL] [Abstract][Full Text] [Related]
4. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
[TBL] [Abstract][Full Text] [Related]
5. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
[TBL] [Abstract][Full Text] [Related]
6. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.
Noel GJ; Goodman DB; Chien S; Solanki B; Padmanabhan M; Natarajan J
J Clin Pharmacol; 2004 May; 44(5):464-73. PubMed ID: 15102866
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors.
Smith DC; Powderly J; Lee JJ; Shepard DR; Wallin J; Chaudhary A; Chao GY; Ng WT; Mitchell MI; Grau G; Kurek R; LoRusso P
Cancer Chemother Pharmacol; 2016 Aug; 78(2):271-80. PubMed ID: 27312733
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR.
Munasinghe WP; Mittapalli RK; Li H; Hoffman DM; Holen KD; Menon RM; Xiong H
Cancer Chemother Pharmacol; 2017 May; 79(5):915-922. PubMed ID: 28349167
[TBL] [Abstract][Full Text] [Related]
9. Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval).
Morganroth J; Shah RR; Scott JW
Clin Pharmacol Ther; 2010 Feb; 87(2):166-74. PubMed ID: 20010556
[TBL] [Abstract][Full Text] [Related]
10. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
[TBL] [Abstract][Full Text] [Related]
11. Late potentials and QT dispersion after high-dose chemotherapy in patients with non-Hodgkin lymphoma.
Kuittinen T; Jantunen E; Vanninen E; Mussalo H; Nousiainen T; Hartikainen J
Clin Physiol Funct Imaging; 2010 May; 30(3):175-80. PubMed ID: 20132128
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors.
Patel C; Goel S; Patel MR; Rangachari L; Wilbur JD; Shou Y; Venkatakrishnan K; Lockhart AC
Clin Pharmacol Drug Dev; 2020 Oct; 9(7):876-888. PubMed ID: 32488989
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer.
Cooney MM; Radivoyevitch T; Dowlati A; Overmoyer B; Levitan N; Robertson K; Levine SL; DeCaro K; Buchter C; Taylor A; Stambler BS; Remick SC
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):96-100. PubMed ID: 14734457
[TBL] [Abstract][Full Text] [Related]
14. Increased incidence of QT interval prolongation in a population receiving lower doses of methadone maintenance therapy.
Roy AK; McCarthy C; Kiernan G; McGorrian C; Keenan E; Mahon NG; Sweeney B
Addiction; 2012 Jun; 107(6):1132-9. PubMed ID: 22168435
[TBL] [Abstract][Full Text] [Related]
15. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study.
Peles E; Bodner G; Kreek MJ; Rados V; Adelson M
Addiction; 2007 Feb; 102(2):289-300. PubMed ID: 17222284
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors.
Tan AR; Moore DF; Hidalgo M; Doroshow JH; Poplin EA; Goodin S; Mauro D; Rubin EH
Clin Cancer Res; 2006 Nov; 12(21):6517-22. PubMed ID: 17065274
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
Lin CC; Calvo E; Papadopoulos KP; Patnaik A; Sarantopoulos J; Mita AC; Preston GG; Mita MM; Rodon J; Mays T; Yeh IT; O'Rourke P; Takimoto CH; Dancey JE; Chen H; Tolcher AW
Cancer Chemother Pharmacol; 2009 May; 63(6):1065-71. PubMed ID: 18795291
[TBL] [Abstract][Full Text] [Related]
18. 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.
McKeage MJ; Fong P; Jeffery M; Baguley BC; Kestell P; Ravic M; Jameson MB
Clin Cancer Res; 2006 Mar; 12(6):1776-84. PubMed ID: 16551862
[TBL] [Abstract][Full Text] [Related]
19. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation.
Milic M; Bao X; Rizos D; Liu F; Ziegler MG
Clin Ther; 2006 Apr; 28(4):582-90. PubMed ID: 16750469
[TBL] [Abstract][Full Text] [Related]
20. Modeling the effect of sevoflurane on corrected QT prolongation: a pharmacodynamic analysis.
Han DW; Park K; Jang SB; Kern SE
Anesthesiology; 2010 Oct; 113(4):806-11. PubMed ID: 20808206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
